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Cost-eﬀectiveness of cognitive self-therapy
in patients with depression and anxiety
disorders
Introduction
Many patients suﬀering from depression and
anxiety disorders cannot be adequately treated
within European healthcare systems (1). The
number of available therapists is limited and
unable to meet the extensive need for care. Unfor-
tunately, the consequences of inadequate treatment
of mental illness can be serious, both for the well-
being of patients as for national healthcare
Stant AD, Ten Vergert EM, den Boer PCAM, Wiersma D. Cost-
eﬀectiveness of cognitive self-therapy in patients with depression and
anxiety disorders.
Objective: Self-therapy interventions could potentially reduce
healthcare expenses and the need for care in the treatment of
depression and anxiety disorders. This study assessed the cost-
eﬀectiveness of cognitive self-therapy (CST) in patients with these
disorders.
Method: A total of 151 patients were randomly assigned to CST or
treatment as usual (TAU), and followed during 18 months. The
Symptom Checklist 90 (SCL-90) was the primary outcome measure of
the study. The reference year was 2003 (US$1.00 = €0.92).
Results: Mean costs of patients in the CST group (US$4364) were
lower than that of the patients who received TAU (US$5241). The
results of the SCL-90 were slightly in favour of CST. Valuing an
additional unit of health outcome at US$108 will lead to an 83%
probability that CST is cost-eﬀective.
Conclusion: Cognitive self-therapy appears to be cost-eﬀective. Wider
implementation of CST may relieve the burden of many patients with
emotional disorders whose treatment needs cannot be met in current
healthcare systems.
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Significant outcomes
• Societal costs assessed during the 18 months of the study favoured CST over TAU.
• Clinical results in the CST group did not differ signiﬁcantly from results in the TAU group, but the
effectiveness of CST appeared to be (at least) comparable with that of TAU.
• Implementation of CST in current healthcare systems will lead to a more efﬁcient use of healthcare
resources.
Limitations
• A non-inferiority design may be more adequate for studies on self-help therapies than the superiority
design applied in the current study.
• Baseline differences between groups on the SCL-90 were not statistically signiﬁcant, but appeared to
be clinically relevant. The conducted statistical analyses corrected for these initial differences.
• There is no consensus on acceptable (cost) benchmarks for additional units of health outcome, like
points gained on the SCL-90 in the current study, which makes policy decisions less straightforward.
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expenses, especially in case of recurring or chronic
mental disorders (2, 3).
Various studies have indicated that self-help
strategies can form an eﬀective alternative for
treatment provided by therapists, also in depres-
sion and anxiety disorders (4). Self-help strategies
are currently provided to patients in diﬀerent
formats, including self-help manuals and comput-
erized programmes. For policy makers, the poten-
tial cost savings associated with self-help strategies
aimed at emotional disorders are particularly
interesting, especially when also considering the
substantial costs these disorders impose on society
(5, 6). Unfortunately, only a limited number of
studies analysed both costs and health outcomes of
self-help strategies in emotional disorders, and the
methodological quality of available studies has
been questioned (7). In one of the few economic
evaluations of self-help strategies in patients with
depression and anxiety disorders (8), the cost-
eﬀectiveness of computerized cognitive behavioural
therapy (CBT) was examined. Based on costs and
health outcomes registered during 8 months, the
authors concluded that computerized CBT was
likely to be cost-eﬀective compared with treatment
as usual (TAU). These ﬁndings underline the
relevance of economic evaluations of self-help
strategies, and provide support for economic
studies on other forms of self-help strategies and
in diﬀerent healthcare settings as well.
Recently, a randomized controlled trial (9)
focused on cognitive self-therapy (CST) in patients
with depression and anxiety disorders. Cognitive
self-therapy integrates self-help manuals and
depression courses with support provided by
paraprofessionals. There were indications of the
eﬀectiveness of CST (based on an unpublished
pilot study), but no large trials had been conducted
earlier.
Aims of the study
This paper presents the results of the economic
evaluation that was performed alongside the clin-
ical study on CST. The economic evaluation
assessed the cost-eﬀectiveness of CST in compar-
ison with TAU in patients with depression and
anxiety disorders.
Material and methods
The economic evaluation was part of an 18-month
randomized controlled trial on the eﬀectiveness of
CST in patients with depression and anxiety
disorders. Details on the design and results of the
clinical study are provided elsewhere (9).
Study population
The recruitment of patients took place between
2000 and 2002 in four outpatient centres located in
diﬀerent parts of the Netherlands. Patients were
eligible for the study if they had a diagnosis of
depression or generalized anxiety disorder. Addi-
tional selection criteria included a history of mental
healthcare utilization of at least 2 years, aged
between 18 and 65, and an awareness of personal
vulnerability in social contacts and ⁄or relation-
ships. Patients were excluded if they displayed
suicidal behaviour or psychotic symptoms, had a
comorbid diagnosis within the autistic spectrum or
an organic disorder, were drug or alcohol depen-
dent, or mentally handicapped (IQ < 85).
Randomization procedure and interventions
Stratiﬁed randomization was applied to ensure the
comparability of patient groups. Strata were based
on age: <40 or ‡40 years of age and duration of
complaints: <7 or ‡7 years. Results of an unpub-
lished pilot study on CST suggested that these
strata would be relevant for the randomization
procedure in subsequent studies. Patients were
randomly assigned to two intervention arms, CST
or TAU. Both interventions were provided in
outpatient centres and included a ﬁrst contact for
diagnostic purposes. During the study, patients
received any form of regular care they required in
addition to the care that was part of the interven-
tions.
Treatment as usual in the Netherlands consisted
of 10–20 contacts with a psychologist, psychiatric
nurse or social worker. During these contacts,
healthcare professionals mainly focused on prob-
lem-solving and coping strategies, but they did not
follow a prescribed treatment protocol.
Cognitive self-therapy is a method developed to
restructure cognitive schemata and address prob-
lems in social functioning and relationships. Psy-
chiatric nurses, social workers and psychologists
can be trained to perform CST programmes and
teach the CST method to patients. Patients use a
CST manual (10) that acquaints them with the
treatment principles. The patients role in the
treatment gradually evolves into that of a para-
professional, such that they ﬁnally conduct CST
sessions in reciprocal relationships with peers. The
CST programme consists of: i) preparatory phase
of one to three 45-min meetings, for informing the
patient and for checking whether the patient is able
and willing to participate in the CST course; ii)
orientation course of three mornings, once in a
week, during which the patients practice with
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peers, before deﬁnitely making the choice to
continue with the next phase; iii) basic course of
5 days, once in a week, in which patients learn to
manage a CST session. Those who perform a CST
session adequately with peers will become certiﬁed
to participate in the last phase of the CST
programme: iv) self-therapy meetings, once in a
week, led by peers in accordance with the manual
as was taught during the basic course. All certiﬁed
patients had the free choice of participating in self-
therapy meetings whenever they liked and could
attend these meetings during the study period.
Before the beginning of the study, the CST
programme was uniformly implemented in all
participating centres.
Outcome measures and power analysis
The Symptom Checklist 90 (SCL-90; 11) was the
main outcome measure of the study. The SCL-90 is
a multi-dimensional self-report inventory that can
identify psychological problems and symptoms of
psychopathology. The total score of the SCL-90 is
based on nine subscales and can range from 90–
450, where lower scores indicate better functioning.
Power analyses were based on characteristics of
this instrument in the patient population under
study; 61 patients were required in each treatment
condition to detect a clinically relevant diﬀerence
of 23 points between groups (SD = 50) with an
alpha of 0.05 and a power of 80%. In total, 151
patients were included in the study to account for
an estimated drop-out rate of 20%. Measurement
took place at 6-month intervals, starting at the time
of inclusion till the end of the follow-up period
18 months later (T0, T6, T12 and T18).
Various additional instruments were adminis-
tered during the clinical study, focusing on depres-
sive symptoms (Beck Depression Inventory; 12),
social anxiety (State-Trait Anxiety Inventory; 13),
social functioning (Groningen Social Disabilities
Schedule; 14) and quality of life (World Health
Organisation Quality of Life Assessment-BREF;
15). For details on these additional instruments,
the reader is referred to the published clinical
results (9). The cost-eﬀectiveness analysis focused
primarily on the SCL-90. Results of economic
analyses addressing the additional outcome mea-
sures were not presented in this paper, as the
results were comparable with those of the main
cost-eﬀectiveness analysis.
Costs and unit prices
The economic evaluation was conducted from a
societal perspective; therefore costs were assessed
both within and outside the healthcare sector.
Table 1 shows the various types of costs that were
registered during the 18 months of the study. Costs
of CST included costs of therapists who were
training, educating and supporting patients during
the various stages of the CST programme. Costs of
travelling and invested time related to the CST
meetings were registered during the study. Costs of
invested time were valued in monetary terms based
on the net income of patients.
Costs of informal care were based on the
monetary valuation of the time invested by rela-
tives or acquaintances in helping or assisting the
patient. Additional costs related to the illness, like
costs of non-prescribed medication, are combined
under the heading out-of-pocket costs. The friction
cost method (16, 17) was applied for estimating
costs associated with productivity losses. When
applying the friction cost method, production
losses are assumed to be conﬁned to the period
needed to replace the sick worker (currently
estimated at 5 months in the Netherlands). Quan-
tities of used resources were registered for all the
patients available at the various times of measure-
ment. The information on costs was primarily
collected by means of a questionnaire previously
used in economic evaluations in mental healthcare
(18). This questionnaire assessed, among others,
number of admissions to psychiatric hospitals,
contacts with psychiatrists and psychologists, and
sick leave days of patients. Additional information,
like medication use, was collected through various
healthcare professionals. To facilitate comparisons
with other economic evaluations, unit prices, i.e.
the price of one unit of each included cost type
(available on request), were mainly based on Dutch
standard prices (19). True costs of used resources
were estimated when standard prices were not
available. All unit prices were based on the price
level in the year 2003. In this paper, costs will be
presented in US$ (US$1.00 = €0.92, based on
conversion rates and purchasing power corrections
recommended by the Organization for Economic
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Cooperation and Development; http://www.oec-
d.org/std/ppp). Reference prices established for
previous years were adjusted to prices of 2003 by
applying the consumer price index.
Cost-effectiveness analysis
In cost-eﬀectiveness analysis, costs and the
primary health outcome associated with an inter-
vention are used to calculate the incremental cost-
eﬀectiveness ratio (ICER) relative to one or more
alternatives (20). In the present study, costs and
health outcomes of patients who received CST
were compared with results of patients in the
TAU condition. Primary outcome measure in
the cost-eﬀectiveness analysis was the SCL-90, the
instrument on which power analyses of the
clinical study were based. Costs per point
improvement on the SCL-90 were expressed by
the ICER:
ICER ¼ ðCCST  CTAUÞðSCL90CST  SCL90TAUÞ
where CCST = mean costs per patient in the CST
group, CTAU = mean costs per patient in the TAU
group, SCL90CST = mean SCL-90 difference
score in the CST group and SCL90TAU = mean
SCL-90 difference score in the TAU group.
When costs and health outcomes are measured
over a long period of time, outcomes are often
discounted in economic studies, as people are
assumed to prefer immediate over postponed
consumption (20). In the current study with a
follow-up of 18 months, discounting would have
had a minor eﬀect on diﬀerences between groups.
Therefore, costs and health outcomes were not
discounted in the standard analyses, but the
inﬂuence of discounting was examined in the
sensitivity analyses. Uncertainty surrounding
the calculated ICER was examined by the boot-
strap method (21). Bootstrapping is an iterative
method that consists of randomly selecting patient
data (with replacement) from the observed popu-
lation to create a simulated distribution of data.
incremental cost-eﬀectiveness ratios were calcu-
lated for each of the bootstrap iterations (5000 in
the present study), simulated values of the mean
estimates for the cost and outcome diﬀerences were
added to the cost-eﬀectiveness plane (CEP) (22).
Finally, cost-eﬀectiveness acceptability curves
(CEACs; 23, 24) were calculated. Cost-eﬀectiveness
acceptability curves inform decision-makers on the
probability that an intervention will be cost-eﬀec-
tive for increasing monetary values placed on an
additional unit of health outcome.
Sensitivity analysis
Various sensitivity analyses were performed to
provide information on the robustness of the
results of the economic evaluation. Discount rates
were varied (4 and 5% instead of 0%) and
consequences for diﬀerences between groups were
examined. Costs of hospital admissions are known
to have a large impact on total costs in mental
healthcare. To examine the uncertainty of this cost
aspect in the current study, costs of hospital
admissions were increased with 20% in one of the
intervention arms, while at the same time being
decreased with 20% in the other. Subsequently,
consequences for diﬀerences in mean total costs
between groups were analysed. Finally, the eco-
nomic analyses were repeated by using a healthcare
perspective instead of a societal perspective,
because of the ongoing (international) debate on
the inclusion and quantiﬁcation of various costs
outside the healthcare sector.
Statistical analysis
Analyses of costs and clinical outcomes were
conducted on an intention-to-treat basis, using
mixed models under the assumption of missingness
at random. Mixed models is a repeated measure-
ment analysis that uses all available data, i.e. also
of patients for whom one or more measurements
are missing. The applied models included main
eﬀects of treatment condition and assessment time
and their interaction, with a random eﬀect of
subject. The baseline score of the SCL-90 was
included to account for initial diﬀerences between
groups.
Between-group baseline characteristics were
analysed with students t-tests for continuous
variables and Pearson chi-square tests for categor-
ical variables. P-values <0.05 were considered
statistically signiﬁcant. All the analyses were car-
ried out with spss 12.0.2 for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
Patient characteristics at baseline
The CST group consisted of 52 women (69%) and
23 men (31%) with a mean age of 40.7 years
(SD = 8.9). In the TAU group there were 48
women (63%) and 28 men (37%) with a mean age
of 41.9 years (SD = 9.1). Main diagnoses in both
groups were depressive disorder (91% in CST,
97% in TAU) and generalized anxiety disorder
(9% in CST, 3% in TAU). More than half of the
Stant et al.
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patients (52%) had a co-morbid diagnosis of a
depressive or anxiety disorder. The number of
years since ﬁrst contact with mental healthcare was
12.2 years (SD = 7.6) in the CST group and
13.1 years (SD = 9.0) in the TAU group. There
were no statistically signiﬁcant diﬀerences between
groups on demographic (gender, age, living situa-
tion, level of education) or clinical characteristics
(primary diagnosis, co-morbidity, time of ﬁrst
psychiatric contact, family psychiatric history) at
baseline.
Service use and costs
Table 2 shows information on medical and non-
medical cost, as well as service use. Means of each
cost type were based on all patients in each group.
If a patient did not make use of a speciﬁc cost type,
costs of US$0 were applied when calculating group
means. In addition, mean costs and number of
patients who actually used the health services are
presented as well.
Total costs (medical and non-medical) of pro-
viding the CST intervention were estimated at
US$824 per patient. These costs consisted of costs
of teaching CST to patients (US$350), as well as
travel and time costs of patients directly related to
the CST meetings (US$474). Costs of psychiatric
hospital admissions, medication use and other out-
patient care contributed substantially to the total
medical costs in both groups. Travel costs and
costs of invested time were assessed when directly
related to the CST intervention. Costs related to
productivity losses, with and without absence from
work, were relatively high in both groups.
Diﬀerences between groups in the number of
contacts with various healthcare professionals were
also analysed separately from the cost analyses.
Signiﬁcant diﬀerences in contacts were only found
for other out-patient care (t = )4.029,
Table 2. Medical and non-medical costs (US$)
during T0–T18
Healthcare services and cost types










Therapy ⁄ training 350 (266) 381 (56) – –
In-patient and semi-inpatient care
Psychiatric hospital admission 727 (4027) 22182 (2) 1675 (8066) 19769 (5)
Day care 2 (12) 96 (1) 91 (382) 1339 (4)
Outpatient and community care
Psychiatrist 75 (140) 171 (27) 89 (150) 210 (25)
Psychologist 155 (229) 287 (33) 201 (351) 457 (26)
Social psychiatric nurse 62 (127) 190 (20) 145 (260) 372 (23)
Social worker 24 (79) 144 (10) 61 (145) 238 (15)
Crisis intervention 2 (19) 150 (1) 5 (27) 150 (2)
Psychiatric home care 9 (73) 567 (1) 36 (274) 2106 (1)
CAD§ 0 (–) 0 (0) 0 (–) 0 (0)
Other out-patient care 270 (695) 967 (17) 881 (1078) 1368 (38)
General health care
General practitioner 83 (197) 120 (42) 47 (105) 96 (29)
Alternative healthcare 24 (74) 205 (7) 29 (133) 345 (5)
Home care 3 (14) 56 (3) 3 (14) 50 (4)
Emergency care 0 (–) 0 (0) 0 (–) 0 (0)
Other general healthcare 25 (118) 222 (7) 20 (73) 168 (7)
Day activity institutions
Day activity centre 39 (186) 969 (2) 0 (–) 0 (0)
Other day activity institutions 0 (–) 0 (0) 0 (–) 0 (0)
Medication
Prescribed medication 277 (338) 393 (43) 473 (506) 582 (48)
Various non-medical costs
Travel costs 19 (26) 27 (42) – –
Time costs 455 (437) 496 (56) – –
Informal care 17 (43) 105 (10) 8 (24) 57 (8)
Out-of-pocket costs 57 (170) 269 (13) 46 (147) 207 (13)
Productivity losses
Paid work 1447 (3087) 4413 (20) 1014 (1865) 2718 (22)
Paid work without absence 248 (1748) 5050 (3) 416 (1832) 2729 (9)
CST, cognitive self-therapy; TAU, treatment as usual.
US$1.00 = €0.92.
Mean costs of persons using the health services and cost types involved (number of patients using these services
between brackets).
§Consultation office for Alcohol and Drugs addiction.
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P < 0.001), which was utilized by considerably
more patients in the TAU than in the CST group
(38 and 17 patients respectively). Other out-patient
care consisted of various types of treatment,
including individual and group therapy and social
skills training.
An overview of total costs during each measure-
ment period and total costs during the 18 months
of the study is presented in Table 3.
The costs of teaching CST to patients in the CST
condition were generated during T0–T6, while the
costs of attending peer meetings mainly took place
during the following periods. During T6–T12,
mean total costs in the CST group were signiﬁ-
cantly lower, partially related to a decreased use of
healthcare services. In the last 6 months of the
study, mean costs slightly increased again in both
groups in comparison with the previous 6 months.
Mean total costs during the entire study period
were US$4364 per patient in the CST group
(median costs US$2443) and US$5241 per patient
in the TAU group (median costs US$2721). Dif-
ferences in mean total costs per measurement
between groups were examined by 95% conﬁdence
intervals (CI) generated by the bootstrap method,
in addition to the longitudinal analyses with mixed
models. Diﬀerences in mean total costs during the
18 months of study were not statistically signiﬁcant
(95% CI lower boundary: )US$4001; upper
boundary: +US$1582) for patients for whom all
the measurements were available. Results of the
mixed model analyses on costs during T0–T18 are
displayed in Table 4.
In the mixed model analyses, a signiﬁcant eﬀect
of time was found, i.e. diﬀerences were found
between costs over time for both groups. However,
there was no signiﬁcant treatment eﬀect, nor was
there a signiﬁcant eﬀect of the interaction between
treatment and time. The fact that no signiﬁcant
diﬀerences between groups were found for costs
should be interpreted with some caution, as the
study was powered (as most economic evaluations)
to demonstrate diﬀerences in health outcomes and
not in costs.
Primary health outcome
Results of the SCL-90, the primary health outcome
measure, are displayed in Table 5. In the mixed
model analyses (Table 4), baseline SCL-90 scores
were included as covariate because of the initial
diﬀerences on this outcome measure between
groups.
The eﬀect of time was signiﬁcant (later assess-
ments showed lower scores in both groups), but
there was no signiﬁcant diﬀerence between treat-
Table 3. Total costs (US$) during the study
Measurement
period
CST group TAU group
95% CIn Mean Median n Mean Median
T0–T6 72 2056 1194 70 2134 918 )1385, +1101
T6–T12 65 877 588 62 1547 796 )1470, )36
T12–T18 63 1214 385 61 1820 445 )2678, +1041
T0–T18§ 61 4364 2443 59 5241 2721 )4001, +1582
CST, cognitive self-therapy; TAU, treatment as usual; CI, confidence interval.
US$1.00 = €0.92.
95% confidence interval of the mean cost differences between groups per measurement, generated by the bootstrap
method. Lower and upper boundaries are presented.
§Displayed mean total costs during T0–T18 are based on data of patients for whom all the relevant measurements
were available (complete cases).
Table 4. ANOVA table based on mixed effect analyses of costs and Symptom
Checklist 90 (SCL-90) results
Outcome measure with model effects df F P
Costs
Effects
Intervention 1, 138 0.04 0.85
Time 2, 258 32.14 <0.001
Intervention · time 2, 258 0.63 0.53
SCL-90
Effects
Intervention 1, 148 0.57 0.45
Time 3, 379 31.50 <0.001
Intervention · time 3, 379 0.13 0.90
Mixed effect analyses included a random effect of subject. Differences at baseline
were corrected by means of covariance adjustment for SCL-90 results
Table 5. Results of the SCL-90, means and standard deviations
Measurement
CST group TAU group
n Mean (SD) n Mean (SD)
T0 75 217.5 (54.2) 76 238.8 (58.6)
T6 70 184.7 (60.4) 71 211.0 (70.9)
T12 64 182.9 (68.8) 59 201.2 (79.7)
T18 62 178.5 (66.9) 59 200.3 (75.6)
CST, cognitive self-therapy; TAU, treatment as usual.
Lower scores indicate better functioning.
Stant et al.
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ments, nor a signiﬁcant eﬀect of the interaction
between treatment and time.
Cost-effectiveness analysis
The point estimate of the ICER and the results of
the bootstrap analyses are presented in the CEP in
Fig. 1. The calculated value of the ICER was
)US$156 per point improvement on the SCL-90.
Here, the negative value indicates that CST was
associated with lower mean costs and better health
outcomes. For each quadrant of the CEP, infor-
mation is provided on the percentage of bootstrap
simulations located in that quadrant.
Approximately 50% of the estimated mean cost
and eﬀect diﬀerences were located in the southeast
quadrant. In other words, CST dominated TAU in
50% of the cases. Interpretation of outcomes in the
northeast and southwest quadrants depends on
how much decision-makers are willing to pay for
an additional unit of health outcome. Figure 2
shows the probability that CST will be cost-
eﬀective for increasing monetary values placed on
an additional unit of health outcome. When
decision-makers are willing to pay US$108 per
point improvement on the SCL-90, the probability
that CST will be cost-eﬀective increases up to 83%,
and subsequently decreases. This decrease is due to
the location of the joint density in the northeast
and southwest quadrants of the CEP (24).
Sensitivity analyses
In the ﬁrst type of sensitivity analysis, discount
rates were varied and consequences for diﬀerences
in mean total costs between groups were studied.
Costs were discounted at 4 and 5%, instead of 0%
in the standard analyses. Diﬀerences in mean total
costs between groups were slightly smaller, i.e.




























Fig. 1. Results of the cost-effectiveness










































Fig. 2. Cost-effectiveness acceptability
curve.
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(0%) in favour of CST in the standard analyses.
Other sensitivity analyses focused on variations in
costs of hospital admissions, a cost category that
may contribute considerably to the total amount of
costs in mental healthcare (24% of the total costs
in the current study). First, these costs were
increased with 20% in the CST group, while at
the same time being decreased with 20% in the
TAU group. Subsequently, hospital costs were
decreased by 20% in CST and increased in the
TAU condition. The consequences of these varia-
tions for diﬀerences in mean total costs between
groups were examined. Conﬁdence intervals esti-
mated by the bootstrap method indicated that
mean cost diﬀerences between groups (US$396 and
US$1357 in favour of CST respectively) were not
signiﬁcant. Finally, economic analyses were
repeated using a healthcare perspective instead of
the broader societal perspective applied in the
standard analysis. When only focusing on direct
medical costs, mean total costs were US$2120 in
the CST group and US$3757 in the TAU group. In
this alternative analysis, diﬀerences in mean total
costs between groups (US$1637, 95% CI lower
boundary: )US$4143; upper boundary: +US$341)
were more pronounced than in the standard
analyses (US$877).
Discussion
This paper presented the results of the cost-
eﬀectiveness analysis that was part of an
18-month clinical study focusing on CST in
patients with depression and anxiety disorders. A
comparison was made between costs and health
outcomes of patients who were randomly assigned
to one of the two treatment arms, CST or TAU.
The mean total costs of patients in the CST
group were US$877 lower than the costs of patients
in TAU. Cost types that contributed considerably
to the total amount of costs were related to
hospital admissions, medication use and other
out-patient care (which included various forms of
individual and group therapy, as well as social
skills training). Furthermore, costs of productivity
losses with or without absence from work were
relatively high, which is in line with the results of
previous studies examining (societal) costs of
patients with depression and anxiety disorders (5,
25, 26). The costs of training therapists in CST
were not included in the study. However, training
costs will be relevant for decision-makers when
considering the implementation of CST in current
healthcare systems.
The primary outcome measure of the cost-
eﬀectiveness analysis was the SCL-90. Diﬀerences
between groups on the SCL-90 were smaller than
the expected clinically relevant diﬀerence on which
power analyses during the design phase of the
study were based. The various instruments admin-
istered in addition to the SCL-90 showed results
comparable with the primary outcome measure (9).
The overall outcomes of these instruments, which
measured depressive symptoms, social anxiety,
social functioning and quality of life, demonstrated
that there were no statistically signiﬁcant diﬀer-
ences between groups on these aspects of health.
Additional economic analyses focusing on these
secondary outcome measures led to similar results
(and conclusions) as the presented cost-eﬀective-
ness analysis, and were therefore not added to the
current paper. As also indicated by a recent
literature overview (4), self-help strategies are
commonly associated with clinical results that
seem comparable with those of other treatments.
Consequently, using a superiority design, i.e.
intending to ﬁnd (signiﬁcant) diﬀerences between
interventions, may no longer be the preferred
approach for studies focusing on self-help strate-
gies. Especially since failure to demonstrate supe-
riority does not allow one to conclude that two
interventions are in fact comparable or equal.
Therefore, it may be more appropriate for studies
on self-help strategies to use alternative study
designs, like for instance a non-inferiority design.
Non-inferiority studies intend to show that an
intervention is at least equal to an alternative in
terms of eﬀectiveness (27). Non-inferiority designs
can be applied when there are other advantages to
be gained from an intervention than strictly
improving eﬀectiveness, for instance, when an
intervention is associated with lower healthcare
costs, as seems to be the case for self-help strate-
gies.
Because of various ethical and practical reasons,
power analyses of economic evaluations are usually
based on clinical outcomes in the patient popula-
tion under study, and not on costs (28). Conse-
quently, most economic studies are underpowered
to identify statistically signiﬁcant diﬀerences in
costs, as the skewed distribution of costs (and high
variance) requires larger sample sizes than com-
parisons of clinical outcomes. This was also a
limitation in the current study, where power
analyses were based on the SCL-90. In the
economic analyses focusing on the balance between
costs and health outcomes, a Bayesian approach
was applied that allows for probability statements
(instead of signiﬁcance testing) that are considered
highly relevant and appropriate in the context of
decision-making. CEACs were assessed to present
information on the probability that CST will be
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cost-eﬀective for an increasing willingness to pay
per unit of health outcome gained. Unfortunately,
there is no international consensus on acceptable
benchmarks for an additional unit of health
outcome, neither for generic outcomes as the
quality-adjusted life years (QALY) nor for more
speciﬁc outcomes like the SCL-90 applied in the
current study. Decision-makers will therefore have
to interpret whether the indicated costs per addi-
tional unit of health outcome seem acceptable or
not. In the current study, the probability that CST
will be cost-eﬀective increased from approximately
71 to 83%, depending on the decision-makers
willingness to pay (ranging from US$1 up to
US$108 per additional unit of health respectively).
Such outcomes seem to favour a wider implemen-
tation of the studied intervention. Also the results
of various sensitivity analyses (including analyses
conducted from a healthcare perspective) were
strongly in favour of CST, thereby providing
further support for a more widespread use of this
intervention.
Results of longitudinal studies can be biased by
missing data because of patients who drop-out or
are lost to follow-up (29). Recently, the potential
impact of missing data has also been acknowledged
in the area of economic evaluation (30). In the
current study, mixed models were used for longi-
tudinal analyses of costs and health outcomes to
deal with missing data. In these analyses, baseline
results of the SCL-90 were included as covariate to
correct for initial diﬀerences between groups.
Comparing the overall outcomes of the current
cost-eﬀectiveness analysis with other economic
studies on self-help treatments is complicated
because of the limited follow-up period of pub-
lished studies. The time horizon of available studies
typically ranges from 3 to 8 months (7, 8). Con-
clusions based on such short study periods should
be interpreted with some caution. Especially as
initial positive consequences of psychiatric inter-
ventions may diminish over time (31). In the
present study, costs of patients slowly increased
again in the last 6 months of the study, after a drop
in service use during the previous measurement
period (which was most pronounced in the CST
group). This increase in costs during the last
6 months may reﬂect ﬂuctuations in healthcare
utilization because of the chronic nature of the
illness under study. In the light of observed
changes over time, it seems that study periods of
at least 12–18 months are essential for economic
studies in the ﬁeld of mental healthcare to ade-
quately inform decision-makers.
The current study demonstrated that CST
appears to be a cost-eﬀective intervention that
should be considered for a wider implementation in
current healthcare systems. Moreover, CST could
be applied to relieve the burden of many patients
with depression and anxiety disorders who cur-
rently do not receive the necessary care because of
a limited number of available therapists. Future
economic studies focusing on self-help strategies
(for instance in primary care patients with a ﬁrst
episode of depression) may proﬁt from the sugges-
tions made in the present paper, including the use
of a non-inferiority design and a follow-up period
of at least 12–18 months.
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